Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.</li><li>The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.</li><li>Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.</li></ul>

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.

Albertsons Companies: An Insight Into Its Technology

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>The <a href="https://www.smartkarma.com/entities/seven-i-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:1041:1" rel="noopener">Seven &amp; I Holdings (3382 JP)</a> AGM was a vote of confidence in the Board’s strategy of pursuing two parallel paths to generate value.  </li>
<li>The Board’s management initiatives are steadily being implemented, but have yet to deliver shareholder value. Since they were announced, the share price has modestly outperformed the Nikkei 225.</li>
<li>7&amp;I and Couche Tard signed an NDA but a viable divestiture plan to gain US regulatory approval remains in doubt, particularly as PE has emerged as the likely bidder. </li>
</ul>


The Seven &amp; I Holdings (3382 JP) AGM was a vote of confidence in the Board’s strategy of pursuing two parallel paths to generate value.  
The Board’s management initiatives are steadily being implemented, but have yet to deliver shareholder value. Since they were announced, the share price has modestly outperformed the Nikkei 225.
7&amp;I and Couche Tard signed an NDA but a viable divestiture plan to gain US regulatory approval remains in doubt, particularly as PE has emerged as the likely bidder. 


Seven & I Holdings (3382 JP): Wait and Hope

<ul><li>Albertsons Companies recently reported its fourth quarter and fiscal year-end 2024 results, revealing mixed financial metrics and future prospects.</li><li>The company achieved an identical (ID) sales growth of 2.3%, primarily driven by a significant 18% increase in pharmacy sales and a robust 24% rise in digital sales.</li><li>Despite the top-line growth, gross margins, excluding fuel and LIFO expense, decreased by 45 basis points due to increased healthcare sales and delivery costs, offset partly by productivity gains.</li></ul>

Albertsons Companies recently reported its fourth quarter and fiscal year-end 2024 results, revealing mixed financial metrics and future prospects.The company achieved an identical (ID) sales growth of 2.3%, primarily driven by a significant 18% increase in pharmacy sales and a robust 24% rise in digital sales.Despite the top-line growth, gross margins, excluding fuel and LIFO expense, decreased by 45 basis points due to increased healthcare sales and delivery costs, offset partly by productivity gains.

Albertsons Is Expanding Profits & Winning Big with Smart Pricing & Cutting-Edge Technology!

<ul><li>Albertsons Companies' third quarter 2024 results showcase a strategically mixed performance with several growth initiatives balanced by ongoing challenges.</li><li>Despite the termination of the merger, the company continues to execute its Customers for Life strategy, focusing on digital transformation, customer loyalty, and enhancing the overall value proposition.</li><li>Financially, Albertsons reported a 2% increase in identical sales, driven notably by a 13% rise in pharmacy sales and 23% growth in digital sales.</li></ul>

Albertsons Companies' third quarter 2024 results showcase a strategically mixed performance with several growth initiatives balanced by ongoing challenges.Despite the termination of the merger, the company continues to execute its Customers for Life strategy, focusing on digital transformation, customer loyalty, and enhancing the overall value proposition.Financially, Albertsons reported a 2% increase in identical sales, driven notably by a 13% rise in pharmacy sales and 23% growth in digital sales.

Albertsons Companies: How Are They Managing Growth in Pharmacy and E-commerce Despite Solid Competition?

<ul>
<li>
<a href="https://www.smartkarma.com/entities/seven-i-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:1041:1" rel="noopener">Seven &amp; I Holdings (3382 JP)</a> has published two documents to respond to misinformation and detail its "<em>constructive engagement</em>" with <a href="https://www.smartkarma.com/entities/alimentation-couche-tard-inc" target="_blank" data-smartkarma-citation="entities:25103:1" rel="noopener">Alimentation Couche-Tard (ATD CN)</a>.</li>
<li>The statements underscore the Board’s serious doubts about securing US antitrust approval. The significant discrepancies in the engagement timeline point to two parties at loggerheads. </li>
<li>While the Board claims it is pursuing a dual-track process to create value, the reality is that the process is designed to hinder Couche-Tard's offer to facilitate the restructuring plan.</li>
</ul>



Seven &amp; I Holdings (3382 JP) has published two documents to respond to misinformation and detail its "constructive engagement" with Alimentation Couche-Tard (ATD CN).
The statements underscore the Board’s serious doubts about securing US antitrust approval. The significant discrepancies in the engagement timeline point to two parties at loggerheads. 
While the Board claims it is pursuing a dual-track process to create value, the reality is that the process is designed to hinder Couche-Tard's offer to facilitate the restructuring plan.


Seven & I Holdings (3382 JP): Uncomfortable Truths

United States

Albertsons Companies, Inc. retails food and drugs products. The Company distributes fruits, vegetables, canned items, medicines, and other related goods. Albertsons serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Albertsons Cos (ACI US)

Albertsons Companies: An Insight Into Its Technology

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious...

Baptista Research

Seven & I Holdings (3382 JP): Wait and Hope

The AGM was a vote of confidence in the Board's plan. However, the effectiveness of the management initiatives remains uncertain, and a Couche-Tard...

Arun George

Albertsons Is Expanding Profits & Winning Big with Smart Pricing & Cutting-Edge Technology!

Albertsons Companies recently reported its fourth quarter and fiscal year-end 2024 results, revealing mixed financial metrics and future...

Baptista Research

Albertsons Companies: How Are They Managing Growth in Pharmacy and E-commerce Despite Solid Competition?

Albertsons Companies' third quarter 2024 results showcase a strategically mixed performance with several growth initiatives balanced by ongoing...

Baptista Research

Seven & I Holdings (3382 JP): Uncomfortable Truths

The statements underscore the Board’s serious doubts about securing US antitrust approval. The significant discrepancies in the engagement timeline...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)